– USA, MI – Zomedica Pharmaceuticals Corp. (NYSE: ZOM), a veterinary health company, today announced that Robert Cohen, Interim CEO, has been appointed to the Board of Directors, alongside Christopher Wolfenberg of the law firm Fasken Martineau DuMoulin LLP, also appointed to the Board of Directors.
“Since Rob joined the Company, the Board has been pleased with how quickly he has had a positive impact on our efforts and immersed himself in all of the critical tasks that will lead to our commercial success,” said Board Chairman, Jeff Rowe. “I am pleased to welcome both him and Chris to the Board of Directors, and look forward to working together to bring Zomedica’s TRUFORMA technology platform to market.”
Mr. Cohen joined Zomedica in June of 2020 following successfully serving as President and Chief Executive Officer at a series of early-stage medical device and biotechnology companies. Prior to his 20 years in the CEO position, he was a member of senior management at large multinationals including St. Jude Medical, Inc., Sulzermedica, and Pfizer Inc.
Mr. Wolfenberg is a leading business lawyer in Calgary, Canada focused on public and private securities transactions in the technology, energy and mining industries. Named by Acritas as a “Star Lawyer,” he acts as a Director and Officer of a number of public, private, and not-for-profit entities.
About Zomedica Pharmaceuticals
Based in Ann Arbor, Michigan, Zomedica is a veterinary health company creating products for companion animals by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio will include innovative diagnostics and therapeutics that emphasize patient health and practice health. With a team that includes clinical veterinary professionals, it is Zomedica’s mission to provide veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care.
For more information: https://zomedica.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.